BEDFORD, Mass. -- (BUSINESS WIRE) -- Beryllium announced today its formation as it recently finalized its consolidation of restructured assets from Emerald Bio and deCODE Genetics. With this restructuring, Beryllium emerges as a company positioned to address the market need for collaborative drug discovery. Beryllium has combined extensive target-based drug discovery expertise, comprehensive disease pathways knowledge, deep experience in protein characterization and diverse technological capabilities. The company also announced today it is building out its team of world-class drug discovery professionals. Industry veteran Dalia Cohen has joined Beryllium as the company’s head of research, and additionally, Daniel Kemp, Arturo Morales and Thomas Roddy have joined the company’s leadership team.
“Beryllium’s vision is to enable novel drug discovery through integrated, multi-disciplinary partnerships, deep expertise and proven market experience,” said Johan Pontin, chief executive officer of Beryllium. “Our new name is derived from the naturally-occurring chemical element, Beryllium, which exists only in combination with other elements of the periodic table. We are working in partnership with biopharmaceutical companies and organizations of all sizes around the world to address the most difficult scientific and business challenges facing drug discovery. To help accomplish this important work, we have significantly grown our leadership team.”
Collectively, Beryllium’s staff has been instrumental in taking hundreds of targets to lead compounds and 28 drug candidates into clinical development, covering all therapeutic areas. The newest members of the Beryllium team are as follows:
“Beryllium’s team is well-positioned to take advantage of the evolving industry landscape,” said Cohen. “Industry changes are altering the progression from discovery to development. We are seeing large pharmaceutical companies looking for ways to boost their development pipelines with less risk and entrepreneurial, small companies are now developing virtual models that are based on focused therapeutic development. These changes, along with academic and research organizations suffering from decreases in government funding, have provided an opportunity for a team with a successful track record to open the door to both genetically- and clinically-validated targets, and in developing new therapeutic modalities.”
“We are thrilled to welcome Dalia, Dan, Art and Tom to our team,” continued Pontin. “Dalia’s leadership in complex target discovery and validation will prove endlessly valuable as we tackle challenging drug targets with our collaborators. Dan and Tom’s deep expertise in target discovery and early clinical development will help our company excel at driving critical drug discovery projects across the finish line. And, finally, Art’s leadership experience in informatics will play a key role in Beryllium’s efforts to optimally utilize and apply our growing knowledge base.”
Beryllium is shaping the future of collaborative drug discovery. Our proven teams of drug discovery professionals are passionate about unlocking the therapeutic potential of both genetically- and clinically-validated drug targets, and in developing new therapeutic modalities. We work in partnership with our clients to address the most difficult scientific and business challenges facing drug discovery, and to ultimately enable transformational health care outcomes. www.Be4.com